Concert Genetic Oncology: Cancer Screening

Genetic and biomarker cancer screening tests (stool DNA/FIT‑DNA such as Cologuard, urine‑based assays like PolypDx, and select blood‑based and circulating biomarker assays) to stratify asymptomatic individuals into lower- or higher-risk categories and to screen individuals known to be at increased risk for specific cancers. Coverage is focused on average‑risk adults (e.g., FIT‑DNA for ages ≥45, routine screening 45–75 with individualized decisions 76–85) and higher‑risk patients where specified, but these tests are not diagnostic and positive results require confirmatory diagnostic testing (e.g., colonoscopy); many blood‑ and urine‑based colorectal and lung biomarker screens are considered investigational and not covered.

"Genetic and biomarker tests to screen asymptomatic individuals at average risk for specific cancers."

Sign up to see full coverage criteria, indications, and limitations.